Literature DB >> 6218163

The binding properties of human complement component C1q. Interaction with mucopolysaccharides.

S Almeda, R D Rosenberg, D H Bing.   

Abstract

Quantitative measurements have been made of the interaction of human complement subcomponent C1q with mucopolysaccharides. The binding of C1q to heparin was quantitatively examined by utilizing an assay that employs a 125I-labeled low molecular weight heparin glycosaminoglycan (LMW-Hep) (Mr = 8500). Two classes of binding sites were detected. The first class of sites bound 2.02 mol of LMW-Hep/mol of C1q with a Kd of 76.6 nM. The second class of sites complexes with 12 mol of LMW-Hep with a Kd of 1.01 microM. The higher affinity-binding site for LMW-Hep could be assigned to the collagenous region of C1q (C1q-c); 2.2 mol of 125I-LMW-Hep were bound/mol of purified isolated C1q-c with a Kd = 381 nM. In contrast, the isolated C1q globular region did not bind to 125I-LMW-Hep. The binding of LMW-Hep to C1q and the C1q-c region was confirmed by fluorescence polarization experiments; C1q and C1q-c bound 2.3 and 2.02 mol of fluorescamine-labeled LMW-Hep/mol of protein, respectively. A variety of mucopolysaccharides were able to inhibit interaction of C1q with 125I-LMW-Hep, the most effective being heparan sulfate and dermatan sulfate. LMW-Hep (2.5 nM) inhibited the ability of C1q (0.5 nM) to recombine with C1r (1.4 nM) and C1s (1.6 nM) to form hemolytically active C1. At 250 mM, LMW-Hep inhibited the hemolytic activity of reconstituted C1. The ability of mucopolysaccharides to interact with purified C1q suggests a role for such molecules in the regulation of the first component of complement.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6218163

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  16 in total

1.  Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium.

Authors:  Roberta Bulla; Chiara Agostinis; Fleur Bossi; Lucia Rizzi; Alessandra Debeus; Claudio Tripodo; Oriano Radillo; Francesco De Seta; Berhane Ghebrehiwet; Francesco Tedesco
Journal:  Mol Immunol       Date:  2008-03-04       Impact factor: 4.407

2.  Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance.

Authors:  Haining Yu; Eva M Muñoz; R Erik Edens; Robert J Linhardt
Journal:  Biochim Biophys Acta       Date:  2005-08-15

3.  Identification of the Raji cell membrane-derived C1q inhibitor as a receptor for human C1q. Purification and immunochemical characterization.

Authors:  B Ghebrehiwet; L Silvestri; C McDevitt
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

4.  Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals.

Authors:  Pavel Katsel; Weilun Tan; Vahram Haroutunian
Journal:  PLoS One       Date:  2009-10-29       Impact factor: 3.240

5.  Continual low-level activation of the classical complement pathway.

Authors:  A P Manderson; M C Pickering; M Botto; M J Walport; C R Parish
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

6.  Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain.

Authors:  H Jiang; F A Robey; H Gewurz
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

Review 7.  Emerging and Novel Functions of Complement Protein C1q.

Authors:  Lubna Kouser; Shanmuga Priyaa Madhukaran; Abhishek Shastri; Anuvinder Saraon; Janez Ferluga; Maha Al-Mozaini; Uday Kishore
Journal:  Front Immunol       Date:  2015-06-29       Impact factor: 7.561

8.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12

9.  Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells.

Authors:  Qunying Hong; Chun-I Sze; Sing-Ru Lin; Ming-Hui Lee; Ruei-Yu He; Lori Schultz; Jean-Yun Chang; Shean-Jen Chen; Robert J Boackle; Li-Jin Hsu; Nan-Shan Chang
Journal:  PLoS One       Date:  2009-06-01       Impact factor: 3.240

Review 10.  Neuronal death in Alzheimer's disease and therapeutic opportunities.

Authors:  Rossen Donev; Martin Kolev; Bruno Millet; Johannes Thome
Journal:  J Cell Mol Med       Date:  2009-09-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.